Drugs / PM1003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05862831 | Sep 2021 → Sep 2025 | cancer | BioNTech SE | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PM1003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05862831 ↗ |
| Modality | Monoclonal antibody | “PM1003 is a Bispecific Antibody Targeting PD-L1 and 4-1BB.” NCT05862831 ↗ |
| Route | Intravenous | “Subjects will receive PM1003 by intravenous administration.” NCT05862831 ↗ |